Free Trial
NASDAQ:BLUE

bluebird bio Q1 2023 Earnings Report

bluebird bio logo
$4.14 -0.01 (-0.24%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$4.16 +0.02 (+0.36%)
As of 04/17/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

bluebird bio EPS Results

Actual EPS
$4.20
Consensus EPS
-$10.80
Beat/Miss
Beat by +$15.00
One Year Ago EPS
-$33.20

bluebird bio Revenue Results

Actual Revenue
$2.40 million
Expected Revenue
$26.97 million
Beat/Miss
Missed by -$24.57 million
YoY Revenue Growth
+26.30%

bluebird bio Announcement Details

Quarter
Q1 2023
Time
Before Market Opens
Conference Call Date
Tuesday, May 9, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

bluebird bio's next earnings date is estimated for Wednesday, May 7, 2025, based on past reporting schedules.

bluebird bio Earnings Headlines

Ventum Cap Mkts Estimates TSE:EDR FY2027 Earnings
🥾⛏️👷‍♂️ What I Learned From Numerous Mine Visits...
Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining stocks like most gold analyst CFAs, I decided to visit every significant gold mine I could. 10+ site visits later, I've confirmed my theory... That the most profitable mines share three specific characteristics. When you find all three together, the returns can be staggering.
FY2025 Earnings Estimate for TSE:EDR Issued By Raymond James
Research Analysts Issue Forecasts for TSE:EDR Q1 Earnings
Raymond James Issues Positive Estimate for TSE:EDR Earnings
See More Endeavour Silver Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like bluebird bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bluebird bio and other key companies, straight to your email.

About bluebird bio

bluebird bio (NASDAQ:BLUE), a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

View bluebird bio Profile

More Earnings Resources from MarketBeat